Compassionate use in India: access to unapproved cancer medicines

Compassionate use, sometimes called expanded access, is a way for a person with a serious or life-threatening illness to receive a medicine that has not yet been approved, outside a clinical trial. It is meant for situations where standard treatments have been tried or are unsuitable, and where the person cannot join a trial of that medicine. In India, the national drug regulator can permit the import or supply of an unapproved new medicine for a particular patient when a hospital or medical institution applies. It is a separate route from trials, and very few families know it exists. It does not mean the medicine will work, and it carries the uncertainty of any medicine still under study.

Eligibility is decided case by case, and approval is not common. Generally, the person has a serious or life-threatening condition, has no satisfactory approved treatment available, cannot take part in a relevant clinical trial, and has a doctor who believes the potential benefit justifies the possible risks. The medicine is usually one already being studied in later phase trials, with some evidence about safety. The company that makes it must also agree to supply it, and it may decline. Being eligible in principle does not mean a medicine will be available. Your treating oncologist is the right person to judge whether this route is even worth exploring for your situation.

Patients do not usually apply on their own. The process normally starts with your treating oncologist, who reviews whether an unapproved medicine is reasonable, contacts the manufacturer, and works with the hospital to prepare an application to the national drug regulator, often with ethics committee involvement. The application sets out the medical situation, why other options are unsuitable and how the patient will be monitored. If permission is granted, you should receive written information and give informed consent. Costs, including import, may fall on the family, so ask early. Accepting is voluntary, the medicine may not benefit you, and you remain free to change your mind, with your doctor's guidance.

Separate from trials

A route for one patient, outside a study.

Approval is not common

The regulator and the manufacturer must both agree.

Your oncologist leads it

Requests come through a doctor and hospital.

It cannot tell you whether compassionate use is possible for you or for any particular medicine. That depends on your situation, the manufacturer and the regulator.

It also cannot tell you whether an unapproved medicine would help. Nobody can know that in advance.

Why so few families know

Compassionate use is rarely mentioned in routine appointments, partly because it is uncommon and involves paperwork. Many doctors use it only occasionally, if ever. Knowing it exists lets you ask an informed question, even though the answer for most people will be that it is not suitable or not possible.

Trials usually come first

Where a relevant clinical trial exists and you qualify, joining the trial is usually the preferred way to receive an unapproved medicine. Trials offer structured monitoring and add to knowledge. Compassionate use is generally considered when no trial is available, you do not qualify, or the trial cannot be reached.

The evidence behind the medicine

Medicines considered for compassionate use are still being studied. There may be early evidence of safety and some effect, but not enough for approval. Nobody can say whether the medicine will help a particular person. Side effects may also be less well understood than for approved treatments.

Why a company may say no

Manufacturers may decline because supply is limited, the medicine is needed for ongoing trials, early results raise concerns, or they cannot support monitoring. A refusal can be painful, but it is not a judgement about the patient. Your oncologist can explain the reasons if they are shared.

Cost and import

Compassionate supply may be free from the manufacturer or may need to be paid for, including import charges and special storage. Government schemes and insurance may not cover unapproved medicines. Ask about every cost before the application goes ahead, so the family is not caught unprepared.

Timing

Applications involve the doctor, hospital, manufacturer and regulator, and each step takes time. For people who are very unwell, this can be frustrating. Your oncologist can advise whether the process is realistic in your situation and which standard care and support should continue in the meantime.

Consent still matters

Even outside a trial, you should receive clear information about the medicine, what is known and unknown, possible side effects and monitoring. You should give informed consent in a language you understand, and have time to ask questions and discuss the decision with your family.

Monitoring and reporting

Patients receiving compassionate supply are usually monitored closely, and side effects are reported to the regulator and manufacturer. Expect regular checks and blood tests. This monitoring protects you and helps build knowledge about the medicine for others who may need it later. Ask whom to call between checks if you feel unwell.

Supportive care alongside

Whatever route is explored, good supportive care remains essential: pain relief, nutrition, emotional support and treatment of symptoms. These are not a lesser option. For many people with advanced cancer, focusing on comfort and quality of life is a valid and caring choice. Your care team can support either path.

Checking approval status

A medicine approved in another country may still be unapproved in India. Your oncologist can check its status. The Clinical Trials Registry – India may also show whether trials of that medicine are running in India, which could be a more suitable route. Ask your doctor to look this up with you.

Protecting yourself from false hope

Stories online about remarkable responses to unapproved medicines can raise hope that is not supported by evidence. Families under pressure may feel they must try everything. Discuss any story or article with your oncologist, who can separate reliable information from promotion and explain what is realistic.

The decision stays with you

Even if permission is granted, you are free to decide not to go ahead, or to change your mind later with your doctor's guidance. Declining compassionate use does not affect the standard care or support your oncology team provides. Take time to talk it over with family and ask every question before agreeing.

What to do next

Ask your treating oncologist whether any trial or compassionate use route is worth exploring, ask about evidence, costs and timing, and make any decision together with your family and care team.